Vaccines as consolidation therapy for myeloid leukemia

Expert Review of Hematology

Volumn 4, Issue 1, 2011, Pages 37-50

  Alatrash, Gheath ^a   Molldrem, Jeffrey J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

acute myeloid leukemia; allogeneic stem cell transplantation; cell based vaccines; chronic myeloid leukemia; dendritic cell vaccines; leukemia vaccines; peptide vaccines; targeted immunotherapy

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CANCER TESTIS ANTIGEN; CANCER VACCINE; CARBONATE DEHYDRATASE IX; CYTOPLASM PROTEIN; DB126 PEPTIDE; DB221 PEPTIDE; DB235 PEPTIDE; DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; KEYHOLE LIMPET HEMOCYANIN; MUCIN 1; NY ESO 1 PEPTIDE; PEPTIDE VACCINE; PR1 VACCINE; PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA; R3 PEPTIDE; R5 PEPTIDE; RECEPTOR FOR HYALURONIC ACID MEDIATED MOTILITY; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VACCINE; WT1 PEPTIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADJUVANT THERAPY; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN SPECIFICITY; BREAST CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CHRONIC MYELOID LEUKEMIA; DRUG DOSE COMPARISON; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; KIDNEY CARCINOMA; LEUKEMIA; LEUKEMIA CELL; LEUKOPENIA; LUNG CANCER; MORBIDITY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

CANCER VACCINES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOID; PEPTIDES; VACCINES, DNA;

EID: 79951779813     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.10.80     Document Type: Review

References (154)

1. Estey E, Dohner H. Acute myeloid leukaemia. Lancet 368(9550), 1894-1907 (2006). (Pubitemid 44794525)
2. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 362(24), 2260-2270 (2010).
3. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 362(24), 2251-2259 (2010).
4. Marin D. Current status of imatinib as frontline therapy for chronic myeloid leukemia. Semin. Hematol. 47(4), 312-318 (2010).
5. Falkenburg JH, van de Corput L, Marijt EW, Willemze R. Minor histocompatibility antigens in human stem cell transplantation. Exp. Hematol. 31(9), 743-751 (2003). (Pubitemid 37075966)
6. Greiner J, Dohner H, Schmitt M. Cancer vaccines for patients with acute myeloid leukemia-definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Haematologica 91(12), 1653-1661 (2006). (Pubitemid 46039635)
7. Chen W, Norbury CC, Cho Y, Yewdell JW, Bennink JR. Immunoproteasomes shape immunodominance hierarchies of antiviral CD8(+) T cells at the levels of T cell repertoire and presentation of viral antigens. J. Exp. Med. 193(11), 1319-1326 (2001). (Pubitemid 32524782)
8. + T cell responses. Immunity 25(4), 533-543 (2006). (Pubitemid 44529047)
9. Ellis JM, Henson V, Slack R, Ng J, Hartzman RJ, Katovich Hurley C. Frequencies of HLA-A2 alleles in five U.S. population groups. Predominance of A*02011 and identification of HLA-A*0231. Hum. Immunol. 61(3), 334-340 (2000). (Pubitemid 30117803)
10. Rezvani K, Yong AS, Mielke S, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 111(1), 236-242 (2008).
11. Oji Y, Oka Y, Nishida S, et al. WT1 peptide vaccine induces reduction in minimal residual disease in an imatiniβ-treated CML patient. Eur. J. Haematol. 85(4), 358-360 (2010).
12. Moorman AV, Chilton L, Wilkinson J, Ensor HM, Bown N, Proctor SJ. A population-βased cytogenetic study of adults with acute lymphoblastic leukemia. Blood 115(2), 206-214 (2010).
13. Soupir CP, Vergilio JA, Dal Cin P, et al. Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. Am. J. Clin. Pathol. 127(4), 642-650 (2007). (Pubitemid 46587480)
14. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247(4944), 824-830 (1990).
15. Shepherd P, Suffolk R, Halsey J, Allan N. Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival. Br. J. Haematol. 89(3), 546-554 (1995).
16. Bocchia M, Korontsvit T, Xu Q, et al. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 87(9), 3587-3592 (1996). (Pubitemid 26129585)
17. Buzyn A, Ostankovitch M, Zerbib A, et al. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes. Eur. J. Immunol. 27(8), 2066-2072 (1997). (Pubitemid 27346025)
18. Greco G, Fruci D, Accapezzato D, et al. Two brc-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. Leukemia 10(4), 693-699 (1996). (Pubitemid 26144452)
19. Bocchia M, Wentworth PA, Southwood S, et al. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 85(10), 2680-2684 (1995).
20. Pinilla-Ibarz J, Cathcart K, Korontsvit T, et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 95(5), 1781-1787 (2000). (Pubitemid 30120843)
21. + T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates. Blood 90(1), 290-297 (1997). (Pubitemid 27276573)
22. Pawelec G, Max H, Halder T, et al. BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. Blood 88(6), 2118-2124 (1996). (Pubitemid 26307914)
23. Cathcart K, Pinilla-Ibarz J, Korontsvit T, et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 103(3), 1037-1042 (2004). (Pubitemid 38129569)
24. Bocchia M, Gentili S, Abruzzese E, et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 365(9460), 657-662 (2005). (Pubitemid 40260886)
25. Rojas JM, Knight K, Wang L, Clark RE. Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia 21(11), 2287-2295 (2007). (Pubitemid 350011701)
26. Alexander J, Sidney J, Southwood S, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-βlocking peptides. Immunity 1(9), 751-761 (1994).
27. Rosa DS, Tzelepis F, Cunha MG, Soares IS, Rodrigues MM. The pan HLA DR-βinding epitope improves adjuvant-assisted immunization with a recombinant protein containing a malaria vaccine candidate. Immunol. Lett. 92(3), 259-268 (2004). (Pubitemid 38476986)
28. Ressing ME, van Driel WJ, Brandt RM, et al. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J. Immunother. 23(2), 255-266 (2000). (Pubitemid 30165175)
29. Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Roberts W, Scheinberg DA. Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses. Haematologica 90(10), 1324-1332 (2005). (Pubitemid 41503647)
30. Jain N, Reuben JM, Kantarjian H, et al. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a Phase 2 trial. Cancer 115(17), 3924-3934 (2009).
31. Rojas JM, Knight K, Watmough S, et al. BCR-ABL peptide vaccination in healthy subjects: immunological responses are equivalent to those in chronic myeloid leukaemia patients. Leuk. Res. DOI: 10.1016/j.leukres.2010.05.028 (2010) (Epub ahead of print).
32. Rauscher FJ 3rd, Morris JF, Tournay OE, Cook DM, Curran T. Binding of the Wilms tumor locus zinc finger protein to the EGR-1 consensus sequence. Science 250(4985), 1259-1262 (1990). (Pubitemid 120031839)
33. Englert C, Hou X, Maheswaran S, et al. WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J. 14(19), 4662-4675 (1995).
34. Harrington MA, Konicek B, Song A, Xia XL, Fredericks WJ, Rauscher FJ 3rd. Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms tumor locus. J. Biol. Chem. 268(28), 21271-21275 (1993). (Pubitemid 23292317)
35. Hossain A, Nixon M, Kuo MT, Saunders GF. N-terminally truncated WT1 protein with oncogenic properties overexpressed in leukemia. J. Biol. Chem. 281(38), 28122-28130 (2006). (Pubitemid 44414526)
36. Inoue K, Ogawa H, Sonoda Y, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89(4), 1405-1412 (1997). (Pubitemid 27080005)
37. Miwa H, Beran M, Saunders GF. Expression of the Wilms tumor gene (WT1) in human leukemias. Leukemia 6(5), 405-409 (1992).
38. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms tumor locus. Cell 60(3), 509-520 (1990).
39. Oji Y, Miyoshi S, Maeda H, et al. Overexpression of the Wilms tumor gene WT1 in de novo lung cancers. Int. J. Cancer 100(3), 297-303 (2002). (Pubitemid 34728987)
40. Dohi S, Ohno S, Ohno Y, Soma G, Kyo S, Inoue M. Correlation between WT1 expression and cell proliferation in endometrial cancer. Anticancer Res. 29(11), 4887-4891 (2009).
41. Oji Y, Yamamoto H, Nomura M, et al. Overexpression of the Wilms tumor gene WT1 in colorectal adenocarcinoma. Cancer Sci. 94(8), 712-717 (2003). (Pubitemid 37160929)
42. Oka Y, Udaka K, Tsuboi A, et al. Cancer immunotherapy targeting Wilms tumor gene WT1 product. J. Immunol. 164(4), 1873-1880 (2000). (Pubitemid 30108741)
43. Gao L, Xue SA, Hasserjian R, et al. Human cytotoxic T lymphocytes specific for Wilms tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients. Transplantation 75(9), 1429-1436 (2003). (Pubitemid 36597272)
44. Asemissen AM, Keilholz U, Tenzer S, et al. Identification of a highly immunogenic HLA-A*01-βinding T cell epitope of WT1. Clin. Cancer Res. 12(24), 7476-7482 (2006). (Pubitemid 46095423)
45. Li Z, Oka Y, Tsuboi A, et al. Identification of a WT1 protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitope. Microbiol. Immunol. 52(11), 551-558 (2008).
46. Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 95(1), 286-293 (2000). (Pubitemid 30017254)
47. + progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95(7), 2198-2203 (2000). (Pubitemid 30167714)
48. Oka Y, Elisseeva OA, Tsuboi A, et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms tumor gene (WT1) product. Immunogenetics 51(2), 99-107 (2000). (Pubitemid 30150969)
49. + T cells. Microbiol. Immunol. 52(12), 591-600 (2008).
50. Knights AJ, Zaniou A, Rees RC, Pawelec G, Muller L. Prediction of an HLA-DR-βinding peptide derived from Wilms tumour 1 protein and demonstration of in vitro immunogenicity of WT1(124-138)-pulsed dendritic cells generated according to an optimised protocol. Cancer Immunol. Immunother. 51(5), 271-281 (2002). (Pubitemid 34810708)
51. Kobayashi H, Nagato T, Aoki N, et al. Defining MHC class II T helper epitopes for WT1 tumor antigen. Cancer Immunol. Immunother. 55(7), 850-860 (2006).
52. + T lymphocytes in an HLA class II-restricted manner. Blood 106(4), 1415-1418 (2005). (Pubitemid 41129609)
53. Tsuboi A, Oka Y, Udaka K, et al. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-βinding residues. Cancer Immunol. Immunother. 51(11-12), 614-620 (2002). (Pubitemid 35440514)
54. Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl Acad. Sci. USA 101(38), 13885-13890 (2004). (Pubitemid 39298502)
55. Tsuboi A, Oka Y, Osaki T, et al. WT1 peptide-βased immunotherapy for patients with lung cancer: report of two cases. Microbiol. Immunol. 48(3), 175-184 (2004). (Pubitemid 38405079)
56. Oka Y, Tsuboi A, Murakami M, et al. Wilms tumor gene peptide-βased immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int. J. Hematol. 78(1), 56-61 (2003). (Pubitemid 36899903)
57. Mailander V, Scheibenbogen C, Thiel E, Letsch A, Blau IW, Keilholz U. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 18(1), 165-166 (2004). (Pubitemid 38159453)
58. Keilholz U, Letsch A, Busse A, et al. A clinical and immunologic Phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 113(26), 6541-6548 (2009).
59. Molldrem J, Dermime S, Parker K, et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 88(7), 2450-2457 (1996). (Pubitemid 26327493)
60. Borregaard N, Cowland JB. Granules of the human neutrophilic polymorphonuclear leukocyte. Blood 89(10), 3503-3521 (1997). (Pubitemid 27227073)
61. Molldrem JJ, Clave E, Jiang YZ, et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 90(7), 2529-2534 (1997). (Pubitemid 27413460)
62. Molldrem JJ, Lee PP, Wang C, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med. 6(9), 1018-1023 (2000).
63. Qazilbash M, Wieder E, Rios R, et al. Vaccination with the PR1 leukemia-associated antigen can induce complete remission in patients with myeloid leukaemia. Blood 104, 77a (2004) (Abstract 259).
64. Qazilbash MH, Thall PF, Wang X, et al. PR1 peptide vaccination for patients with myeloid leukemias. J. Clin. Oncol. (ASCO Annual Meeting Proceedings) 25, 18S (2007).
65. Greiner J, Ringhoffer M, Taniguchi M, et al. Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia. Exp. Hematol. 30(9), 1029-1035 (2002). (Pubitemid 35286619)
66. Maxwell CA, McCarthy J, Turley E. Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions? J. Cell Sci. 121(Pt 7), 925-932 (2008). (Pubitemid 351639411)
67. Hamilton SR, Fard SF, Paiwand FF, et al. The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells. J. Biol. Chem. 282(22), 16667-16680 (2007). (Pubitemid 47100370)
68. Tolg C, Hamilton SR, Nakrieko KA, et al. Rhamm-/-fibroblasts are defective in CD44-mediated ERK1,2 motogenic signaling, leading to defective skin wound repair. J. Cell Biol. 175(6), 1017-1028 (2006). (Pubitemid 44969206)
69. Samuel SK, Hurta RA, Spearman MA, Wright JA, Turley EA, Greenberg AH. TGF-β 1 stimulation of cell locomotion utilizes the hyaluronan receptor RHAMM and hyaluronan. J. Cell Biol. 123(3), 749-758 (1993).
70. + T cells of HLA-A2-positive patients with acute myeloid leukemia. Blood 106(3), 938-945 (2005). (Pubitemid 41076438)
71. Schmitt M, Schmitt A, Rojewski MT, et al. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood 111(3), 1357-1365 (2008). (Pubitemid 351213422)
72. Greiner J, Schmitt A, Giannopoulos K, et al. High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Haematologica 95(7), 1191-1197 (2010).
73. Blackburn EH. Structure and function of telomeres. Nature 350(6319), 569-573 (1991). (Pubitemid 21912269)
74. Hiyama E, Hiyama K. Telomerase as tumor marker. Cancer Lett. 194(2), 221-233 (2003). (Pubitemid 36577333)
75. Hartmann U, Brummendorf TH, Balabanov S, Thiede C, Illme T, Schaich M. Telomere length and hTERT expression in patients with acute myeloid leukemia correlates with chromosomal abnormalities. Haematologica 90(3), 307-316 (2005). (Pubitemid 40388980)
76. Warner JK, Wang JC, Takenaka K, et al. Direct evidence for cooperating genetic events in the leukemic transformation of normal human hematopoietic cells. Leukemia 19(10), 1794-1805 (2005). (Pubitemid 41486158)
77. Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc. Natl Acad. Sci. USA 97(9), 4796-4801 (2000). (Pubitemid 30238637)
78. Arai J, Yasukawa M, Ohminami H, Kakimoto M, Hasegawa A, Fujita S. Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes. Blood 97(9), 2903-2907 (2001).
79. Schroers R, Shen L, Rollins L, et al. Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin. Cancer Res. 9(13), 4743-4755 (2003). (Pubitemid 37323277)
80. Bernhardt SL, Gjertsen MK, Trachsel S, et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating Phase I/II study. Br. J. Cancer 95(11), 1474-1482 (2006). (Pubitemid 44863349)
81. Brunsvig PF, Aamdal S, Gjertsen MK, et al. Telomerase peptide vaccination: a Phase I/II study in patients with non-small cell lung cancer. Cancer Immunol. Immunother. 55(12), 1553-1564 (2006). (Pubitemid 44327843)
82. Mavroudis D, Bolonakis I, Cornet S, et al. A Phase I study of the optimized cryptic peptide TERT(572y) in patients with advanced malignancies. Oncology 70(4), 306-314 (2006). (Pubitemid 44670173)
83. Gannage M, Abel M, Michallet AS, et al. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. J. Immunol. 174(12), 8210-8218 (2005). (Pubitemid 40806333)
84. Vissers JL, De Vries IJ, Schreurs MW, et al. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res. 59(21), 5554-5559 (1999). (Pubitemid 29526473)
85. Loncaster JA, Harris AL, Davidson SE, et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res. 61(17), 6394-6399 (2001). (Pubitemid 32783244)
86. Grabmaier K, A de Weijert MC, Verhaegh GW, Schalken JA, Oosterwijk E. Strict regulation of CAIX(G250/MN) by HIF-1a in clear cell renal cell carcinoma. Oncogene 23(33), 5624-5631 (2004). (Pubitemid 39093040)
87. Le QT, Chen E, Salim A, et al. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin. Cancer Res. 12(5), 1507-1514 (2006).
88. Troost EG, Bussink J, Kaanders JH, et al. Comparison of different methods of CAIX quantification in relation to hypoxia in three human head and neck tumor lines. Radiother. Oncol. 76(2), 194-199 (2005). (Pubitemid 41725447)
89. Greiner J, Schmitt M, Li L, et al. Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches. Blood 108(13), 4109-4117 (2006). (Pubitemid 44913282)
90. Herbert N, Haferkamp A, Schmitz-Winnenthal HF, Zoller M. Concomitant tumor and autoantigen vaccination supports renal cell carcinoma rejection. J. Immunol. 185(2), 902-916 (2010).
91. Su Z, Dannull J, Heiser A, et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. 63(9), 2127-2133 (2003). (Pubitemid 36538616)
92. Doolan P, Clynes M, Kennedy S, Mehta JP, Crown J, ODriscoll L. Prevalence and prognostic and predictive relevance of PRAME in breast cancer. Breast Cancer Res. Treat. 109(2), 359-365 (2008). (Pubitemid 351644842)
93. Figueiredo DL, Mamede RC, Proto-Siqueira R, Neder L, Silva WA Jr, Zago MA. Expression of cancer testis antigens in head and neck squamous cell carcinomas. Head Neck 28(7), 614-619 (2006). (Pubitemid 44025110)
94. Oberthuer A, Hero B, Spitz R, Berthold F, Fischer M. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin. Cancer Res. 10(13), 4307-4313 (2004). (Pubitemid 38878868)
95. Steinbach D, Hermann J, Viehmann S, Zintl F, Gruhn B. Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet. Cytogenet. 133(2), 118-123 (2002). (Pubitemid 34279642)
96. Steinbach D, Viehmann S, Zintl F, Gruhn B. PRAME gene expression in childhood acute lymphoblastic leukemia. Cancer Genet. Cytogenet. 138(1), 89-91 (2002). (Pubitemid 35292607)
97. De Carvalho DD, Binato R, Pereira WO, et al. BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients. Oncogene 30(2), 223-233 (2010).
98. van Baren N, Chambost H, Ferrant A, et al. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br. J. Haematol. 102(5), 1376-1379 (1998). (Pubitemid 28435230)
99. Ikeda H, Lethe B, Lehmann F, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6(2), 199-208 (1997). (Pubitemid 27145564)
100. Santamaria CM, Chillon MC, Garcia-Sanz R, et al. Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia. Blood 114(1), 148-152 (2009).
101. Oehler VG, Guthrie KA, Cummings CL, et al. The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells. Blood 114(15), 3299-3308 (2009).
102. Radich JP, Dai H, Mao M, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc. Natl Acad. Sci. USA 103(8), 2794-2799 (2006).
103. Kessler JH, Beekman NJ, Bres-Vloemans SA, et al. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J. Exp. Med. 193(1), 73-88 (2001). (Pubitemid 32060699)
104. + T cells specific for PRAME: a target for T-cell therapy. Clin. Cancer Res. 12(10), 3130-3136 (2006). (Pubitemid 43837361)
105. Morita Y, Heike Y, Kawakami M, et al. Monitoring of WT1-specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation. Int. J. Cancer 119(6), 1360-1367 (2006). (Pubitemid 44258812)
106. Quintarelli C, Dotti G, De Angelis B, et al. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood 112(5), 1876-1885 (2008).
107. + T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood 113(10), 2245-2255 (2009).
108. Brossart P, Schneider A, Dill P, et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res. 61(18), 6846-6850 (2001). (Pubitemid 32896509)
109. Brossart P, Heinrich KS, Stuhler G, et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93(12), 4309-4317 (1999). (Pubitemid 29279274)
110. Girling A, Bartkova J, Burchell J, Gendler S, Gillett C, Taylor-Papadimitriou J. A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int. J. Cancer 43(6), 1072-1076 (1989). (Pubitemid 19158040)
111. Brugger W, Schneider A, Schammann T, et al. Dendritic cell-βased vaccines in patients with hematological malignancies. Ann. NY Acad. Sci. 938, 359-363 (2001). (Pubitemid 32620046)
112. Ramanathan RK, Lee KM, McKolanis J, et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol. Immunother. 54(3), 254-264 (2005). (Pubitemid 40174243)
113. Palmer M, Parker J, Modi S, et al. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin. Lung Cancer 3(1), 49-57; discussion 58 (2001). (Pubitemid 32904315)
114. North SA, Graham K, Bodnar D, Venner P. A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy. J. Urol. 176(1), 91-95 (2006). (Pubitemid 43815368)
115. Butts C, Murray N, Maksymiuk A, et al. Randomized Phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J. Clin. Oncol. 23(27), 6674-6681 (2005). (Pubitemid 46190262)
116. + T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT. Bone Marrow Transplant. 43(5), 399-410 (2009).
117. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl Acad. Sci. USA 94(5), 1914-1918 (1997). (Pubitemid 27113936)
118. Stockert E, Jager E, Chen YT, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Med. 187(8), 1349-1354 (1998). (Pubitemid 28189124)
119. Jager E, Chen YT, Drijfhout JW, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-βinding peptide epitopes. J. Exp. Med. 187(2), 265-270 (1998). (Pubitemid 28060443)
120. Odunsi K, Qian F, Matsuzaki J, et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc. Natl Acad. Sci. USA 104(31), 12837-12842 (2007). (Pubitemid 47255241)
121. Khong HT, Yang JC, Topalian SL, et al. Immunization of HLA-A*0201 and/or HLA-DPb1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J. Immunother. 27(6), 472-477 (2004). (Pubitemid 39447355)
122. + T cells in melanoma patients. J. Immunother. 31(8), 781-791 (2008).
123. Bioley G, Guillaume P, Luescher I, et al. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing tumors. J. Immunother. 32(2), 161-168 (2009).
124. Adams SP, Sahota SS, Mijovic A, et al. Frequent expression of HAGE in presentation chronic myeloid leukaemias. Leukemia 16(11), 2238-2242 (2002). (Pubitemid 35331839)
125. Niemeyer P, Tureci O, Eberle T, Graf N, Pfreundschuh M, Sahin U. Expression of serologically identified tumor antigens in acute leukemias. Leuk. Res. 27(7), 655-660 (2003). (Pubitemid 36398102)
126. + T-cell responses and are lacking costimulatory molecules. Exp. Hematol. 34(12), 1709-1719 (2006). (Pubitemid 44839001)
127. Mohty M, Jarrossay D, Lafage-Pochitaloff M, et al. Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment. Blood 98(13), 3750-3756 (2001).
128. Vuckovic S, Fearnley DB, Gunningham S, Spearing RL, Patton WN, Hart DN. Dendritic cells in chronic myelomonocytic leukaemia. Br. J. Haematol. 105(4), 974-985 (1999). (Pubitemid 29309105)
129. Eisendle K, Wolf D, Gastl G, Kircher-Eibl B. Dendritic cells from patients with chronic myeloid leukemia: functional and phenotypic features. Leuk. Lymphoma 46(5), 663-670 (2005). (Pubitemid 40775214)
130. Takahashi T, Tanaka Y, Nieda M, et al. Dendritic cell vaccination for patients with chronic myelogenous leukemia. Leuk. Res. 27(9), 795-802 (2003). (Pubitemid 36683326)
131. Van Driessche A, Van de Velde AL, Nijs G, et al. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a Phase I dose-escalation clinical trial. Cytotherapy 11(5), 653-668 (2009).
132. Van Tendeloo VF, Van de Velde A, Van Driessche A, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms tumor 1 antigen-targeted dendritic cell vaccination. Proc. Natl Acad. Sci. USA 107(31), 13824-13829 (2010).
133. Matheoud D, Perie L, Hoeffel G, et al. Cross-presentation by dendritic cells from live cells induces protective immune responses in vivo. Blood 115(22), 4412-4420 (2010).
134. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 106(3), 255-258 (2001). (Pubitemid 32772607)
135. Ackerman AL, Cresswell P. Cellular mechanisms governing cross-presentation of exogenous antigens. Nat. Immunol 5(7), 678-684 (2004). (Pubitemid 39023296)
136. Zeng Y, Graner MW, Thompson S, Marron M, Katsanis E. Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells. Blood 105(5), 2016-2022 (2005). (Pubitemid 40731786)
137. Weigel BJ, Panoskaltsis-Mortari A, Diers M, et al. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses. Exp. Hematol. 34(10), 1403-1412 (2006). (Pubitemid 44374832)
138. Spisek R, Chevallier P, Morineau N, et al. Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin. Cancer Res. 62(10), 2861-2868 (2002). (Pubitemid 34525772)
139. + cord blood cell-derived and irradiated tumor cell-primed dendritic cells. Int. J. Hematol. 68(2), 169-182 (1998). (Pubitemid 28479941)
140. Jarnjak-Jankovic S, Pettersen RD, Saeboe-Larssen S, Wesenberg F, Gaudernack G. Evaluation of dendritic cells loaded with apoptotic cancer cells or expressing tumour mRNA as potential cancer vaccines against leukemia. BMC Cancer 5, 20 (2005).
141. Lee JJ, Kook H, Park MS, et al. Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation. J. Clin. Apher. 19(2), 66-70 (2004). (Pubitemid 39006610)
142. Kremser A, Dressig J, Grabrucker C, et al. Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods. J. Immunother. 33(2), 185-199 (2010).
143. Li L, Schmitt A, Reinhardt P, et al. Reconstitution of CD40 and CD80 in dendritic cells generated from blasts of patients with acute myeloid leukemia. Cancer Immun. 3, 8 (2003).
144. Westermann J, Kopp J, van Lessen A, et al. Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia. Br. J. Haematol. 137(4), 297-306 (2007). (Pubitemid 46650246)
145. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA 90(8), 3539-3543 (1993). (Pubitemid 23111402)
146. Schwaab T, Tretter CP, Gibson JJ, et al. Tumor-related immunity in prostate cancer patients treated with human recombinant granulocyte monocyte-colony stimulating factor (GM-CSF). Prostate 66(6), 667-674 (2006).
147. Soiffer R, Hodi FS, Haluska F, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J. Clin. Oncol. 21(17), 3343-3350 (2003). (Pubitemid 46606268)
148. Nemunaitis J. Granulocyte-macrophage colony-stimulating factor gene-transfected autologous tumor cell vaccine: focus[correction to fcous] on non-small-cell lung cancer. Clin. Lung Cancer 5(3), 148-157 (2003). (Pubitemid 38028804)
149. Borrello I, Sotomayor EM, Rattis FM, Cooke SK, Gu L, Levitsky HI. Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood 95(10), 3011-3019 (2000). (Pubitemid 30321148)
150. Borrello IM, Levitsky HI, Stock W, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). Blood 114(9), 1736-1745 (2009).
151. Simons JW, Sacks N. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol. Oncol. 24(5), 419-424 (2006). (Pubitemid 44311548)
152. Small EJ, Sacks N, Nemunaitis J, et al. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin. Cancer Res. 13(13), 3883-3891 (2007). (Pubitemid 47037595)
153. Le DT, Pardoll DM, Jaffee EM. Cellular vaccine approaches. Cancer J. 16(4), 304-310 (2010).
154. SEER: Surveillance, Epidemiology and End Results http://seer.cancer.gov (Accessed July 2010)